Selatox to Begin Botulinum Toxin Production After Securing GMP Certification

CIKARANG, Jakartaweekly.com — PT Selatox Bio Pharma is set to begin producing and exporting botulinum toxin after its manufacturing facility obtained Good Manufacturing Practice (GMP) certification from the Indonesian government through the Food and Drug Authority (BPOM).

Selatox Bio Pharma Chief Executive Officer Joh Young-hoon said the company’s plant currently has an annual production capacity of 6.5 million vials.

“Our next step is to start production and begin exporting,” he told Jakarta Weekly in Cikarang, West Java, on Monday, July 20, 2026.

At the same time, the company will pursue local product registration to enable its products to be marketed in Indonesia, Joh said. He declined to disclose the company’s first-year sales target, describing the information as confidential.

Despite that, Joh expressed strong confidence in the Indonesian market. He said the country offers significant growth potential, citing its status as the world’s fourth-most populous nation.

He added that Indonesia’s expanding economy, coupled with robust demand for aesthetic treatments and skincare products, reinforces the company’s optimism about the market.

“We are here to meet that demand, and we are very optimistic that this facility will serve the Indonesian market,” he said.

On exports, Joh said the company plans to ship its products to multiple countries, beginning with neighboring markets.

He added that Selatox already operates chemical manufacturing facilities in several other countries. However, botulinum toxin is a highly specialized product subject to stringent government regulation.

“As a result, only a handful of countries in the world have botulinum toxin manufacturing facilities, and Indonesia is now one of them,” he said.

According to Joh, the products manufactured in Indonesia will be produced to the same premium standards as those in South Korea.

He said the company’s botulinum toxin products made in Korea are globally recognized as among the industry’s leading products, and the same technology and quality standards are being transferred to its Indonesian facility.

“We are bringing Korea’s premium standards to Indonesia. Our products made in Korea are already recognized globally as among the best, and we are bringing that technology here to ensure the same level of quality,” he said.

Joh said the company chose Indonesia not only because of its sizeable domestic market but also because of the quality of its workforce.

He said Indonesian workers possess strong educational backgrounds, a solid work ethic, and a high level of dedication, making them well suited to support a biotechnology industry that meets global standards.

He emphasized that the facility was designed from the outset as a production hub rather than solely to supply the domestic market.

“We believe in the capabilities and potential of the Indonesian people. That is why we established this facility as a production hub. We are not only here to serve the Indonesian market, but also to supply the Middle East and other markets around the world,” Joh said.

However, Joh declined to disclose the origin of the raw materials used in the production of botulinum toxin, saying only that both the raw materials and manufacturing process adhere to the same quality standards applied at the company’s facilities in South Korea.